Paragon Labs Absorbs Apogee Leadership to Accelerate Biologics Pipeline

Key points

• Michael Henderson, former CEO of Apogee Therapeutics, has been appointed CEO of Paragon Labs, alongside other former Apogee executives including Carl Dambkowski (R&D), Dan Mulreany (CFO), Matt Batters (Legal), and Emily Cox (People).
• The leadership transition aims to apply lessons learned from Apogee’s clinical-stage development to Paragon’s discovery engine, accelerating the path to market for new biologic candidates.
• Velaris Therapeutics, a Paragon spinout focused on pulmonary hypertension, was acquired by Alaunos Therapeutics in a stock-for-stock transaction.
• The combined entity secured a $350 million private placement led by Fairmount, providing funding through 2029 to advance Velaris’s pipeline, including the lead candidate VLR199.
• This acquisition is the ninth company launched from Paragon-discovered assets, following the $10.9 billion sale of Apogee to AbbVie in 2026.

Background

Paragon Labs, founded in 2021 by life sciences investment firm Fairmount, operates as a drug discovery hub that spins out biotechnology companies around its most promising assets. Previous spinouts include Spyre Therapeutics and Oruka Therapeutics. The current developments follow the 2026 acquisition of Apogee Therapeutics by AbbVie for $10.9 billion, a deal centered on Apogee’s eczema drug zumilokibart, which was originally discovered at Paragon.

How outlets are covering it

Endpoints News highlighted the strategic move of former Apogee executives joining Paragon to scale its R&D and company creation engine, noting the timing shortly after the $10.9 billion AbbVie exit. Fierce Biotech emphasized the comprehensive nature of the leadership transfer, describing it as Paragon taking its pick of top talent from Apogee, and detailed the concurrent acquisition of Velaris by Alaunos. PR Newswire provided the official corporate announcement, framing the leadership expansion as a way to add clinical development and operational expertise to Paragon’s established discovery engine. TipRanks focused on the financial mechanics of the Velaris acquisition, detailing the $350 million private placement and the resulting market capitalization of approximately $555 million for the combined entity.

Why it matters

This consolidation of leadership and capital signals a maturation of Paragon Labs’ business model, moving from pure discovery to integrated clinical development. By absorbing the operational expertise of its most successful spinout, Paragon aims to accelerate the timeline for bringing new biologic therapies to patients. The substantial financing for Velaris also indicates strong investor confidence in the pulmonary hypertension pipeline, potentially challenging existing treatments like Merck’s Winrevair.

What to watch

Paragon Labs will focus on applying the new leadership’s clinical development insights to its current pipeline. Alaunos Therapeutics will utilize the $350 million funding to advance Velaris’s programs, including VLR199, toward proof-of-concept data and IND filings, with operations funded through 2029. The company will also monitor the integration of the new leadership team and the execution of the acquisition’s governance terms.